Status:
UNKNOWN
Bisphosphonates for the Treatment of Seropositive Musculoskeletal Complaints
Lead Sponsor:
Karolinska Institutet
Conditions:
Seropositive Muskuloskeletal Complaints
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Seropositive Rheumatoid arthritis (RA) is characterized by autoantibodies that develop prior to clinical onset, allowing identification of individuals at risk for disease development. In a unique prog...
Detailed Description
we have recently identified a novel disease-triggering pathogenic mechanism in autoantibody-positive individuals consisting in a bone-mediated induction of pain by autoantibodies. We hypothesize that ...
Eligibility Criteria
Inclusion
- Age older than 18 years Lack of arthritis as estimated by clinical and ultrasound examination of the joints ACPA positive Intermediate or high risk for RA (according to the algorithm described above) VAS score of at least 20 mm
Exclusion
- A previous diagnosis of arthritis Intolerance/contraindication to any of the study medications
Key Trial Info
Start Date :
January 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2022
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT04115397
Start Date
January 1 2020
End Date
December 1 2022
Last Update
October 4 2019
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.